ABIVAX Société Anonyme (NASDAQ:ABVX) Receives $36.50 Average Target Price from Brokerages

ABIVAX Société Anonyme (NASDAQ:ABVX) has been given an average recommendation of “Moderate Buy” by the seven ratings firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $36.50.

Separately, Laidlaw started coverage on shares of ABIVAX Société Anonyme in a report on Monday, July 29th. They issued a “buy” rating and a $48.00 target price on the stock.

Institutional Investors Weigh In On ABIVAX Société Anonyme

Institutional investors have recently made changes to their positions in the company. Janus Henderson Group PLC boosted its holdings in ABIVAX Société Anonyme by 18.2% during the 1st quarter. Janus Henderson Group PLC now owns 851,839 shares of the company’s stock valued at $12,113,000 after acquiring an additional 131,414 shares during the period. BNP Paribas Financial Markets purchased a new stake in shares of ABIVAX Société Anonyme during the first quarter valued at $81,000. Kennedy Capital Management LLC boosted its stake in shares of ABIVAX Société Anonyme by 35.3% during the first quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock valued at $1,718,000 after purchasing an additional 31,331 shares during the period. Finally, Capstone Investment Advisors LLC grew its holdings in shares of ABIVAX Société Anonyme by 9.0% in the first quarter. Capstone Investment Advisors LLC now owns 62,966 shares of the company’s stock worth $900,000 after purchasing an additional 5,199 shares during the last quarter. Institutional investors own 47.91% of the company’s stock.

ABIVAX Société Anonyme Stock Performance

Shares of ABVX opened at $10.50 on Thursday. The company’s fifty day moving average is $11.14 and its 200 day moving average is $12.76. ABIVAX Société Anonyme has a fifty-two week low of $7.99 and a fifty-two week high of $17.02.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.